Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$139.63 +5.6%	$131.81	$110.04 ▼ $206.70	$19.39B	0.11	1.29 million shs	2.47 million shs
INCY Incyte	$85.98 +1.6%	$75.78	$53.56 ▼ $87.99	$16.52B	0.75	1.63 million shs	2.21 million shs
IONS Ionis Pharmaceuticals	$57.49 +34.9%	$42.42	$23.95 ▼ $57.92	$6.80B	0.28	1.86 million shs	16.45 million shs
NBIX Neurocrine Biosciences	$141.92 +1.7%	$131.81	$84.23 ▼ $154.61	$13.85B	0.28	725,143 shs	786,333 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	-3.04%	+0.20%	+0.29%	-35.43%
INCY Incyte	0.00%	-0.18%	+11.93%	+26.08%	+28.86%
IONS Ionis Pharmaceuticals	0.00%	+1.94%	-0.93%	+22.64%	-10.59%
NBIX Neurocrine Biosciences	0.00%	+4.19%	+8.29%	+11.68%	+9.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.8614 of 5 stars	4.2	3.0	3.7	2.9	2.5	2.5
INCY Incyte	4.6268 of 5 stars	2.2	2.0	2.8	3.4	3.3	4.4
IONS Ionis Pharmaceuticals	4.4929 of 5 stars	4.4	3.0	3.0	2.7	2.5	0.6
NBIX Neurocrine Biosciences	4.9597 of 5 stars	3.4	5.0	2.9	3.7	2.5	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.34	Hold	$185.74	33.02% Upside
INCY Incyte	2.33	Hold	$81.60	-5.09% Downside
IONS Ionis Pharmaceuticals	2.87	Moderate Buy	$64.73	12.60% Upside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$159.50	12.39% Upside

Current Analyst Ratings Breakdown

Latest IONS, BIIB, INCY, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	IONS Ionis Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$83.00 ➝ $96.00
9/2/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$55.00 ➝ $70.00
9/2/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $95.00
8/25/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$48.00 ➝ $49.00
8/25/2025	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/22/2025	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$67.00 ➝ $73.00
8/22/2025	IONS Ionis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $69.00
8/22/2025	IONS Ionis Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$62.00 ➝ $65.00
8/22/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $58.00
8/22/2025	IONS Ionis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$77.00 ➝ $82.00
8/22/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $70.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.12	$24.41 per share	5.72	$120.28 per share	1.16
INCY Incyte	$4.24B	3.96	$0.56 per share	152.84	$21.36 per share	4.03
IONS Ionis Pharmaceuticals	$705M	13.00	N/A	N/A	$3.96 per share	14.52
NBIX Neurocrine Biosciences	$2.36B	5.98	$3.44 per share	41.30	$27.17 per share	5.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.46	13.35	8.46	1.04	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
INCY Incyte	$32.62M	$4.40	19.54	13.15	0.66	18.99%	21.99%	14.43%	11/4/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$1.84	N/A	N/A	N/A	-28.25%	-45.29%	-8.99%	11/5/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$3.38	41.99	21.94	1.01	13.88%	13.22%	9.39%	10/29/2025 (Estimated)

Latest IONS, BIIB, INCY, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	$0.70	+$0.51	$0.70	$270.90 million	$452.00 million
7/30/2025	Q2 2025	NBIX Neurocrine Biosciences	$0.98	$1.06	+$0.08	$1.06	$653.09 million	$687.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.36	2.50	1.79
INCY Incyte	0.01	2.85	2.78
IONS Ionis Pharmaceuticals	0.99	2.87	2.86
NBIX Neurocrine Biosciences	N/A	3.20	3.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
INCY Incyte	96.97%
IONS Ionis Pharmaceuticals	93.86%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
INCY Incyte	17.80%
IONS Ionis Pharmaceuticals	2.71%
NBIX Neurocrine Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
INCY Incyte	2,617	195.28 million	160.52 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.39 million	155.07 million	Optionable
NBIX Neurocrine Biosciences	1,800	99.18 million	94.92 million	Optionable

IONS, BIIB, INCY, and NBIX Headlines

Recent News About These Companies

Armistice Capital LLC Acquires 108,190 Shares of Neurocrine Biosciences, Inc. $NBIX

September 2 at 8:12 AM | marketbeat.com

Magnetar Financial LLC Makes New $1.10 Million Investment in Neurocrine Biosciences, Inc. $NBIX

September 2 at 6:04 AM | marketbeat.com

Driehaus Capital Management LLC Acquires 5,626 Shares of Neurocrine Biosciences, Inc. $NBIX

September 2 at 5:56 AM | marketbeat.com

Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access

September 2 at 4:48 AM | finance.yahoo.com

CreativeOne Wealth LLC Grows Position in Neurocrine Biosciences, Inc. $NBIX

September 1 at 4:54 AM | marketbeat.com

Kodai Capital Management LP Buys Shares of 85,958 Neurocrine Biosciences, Inc. $NBIX

August 31 at 7:35 AM | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Iron Triangle Partners LP

August 31 at 6:40 AM | marketbeat.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $159.50 Average Target Price from Analysts

August 31 at 2:31 AM | americanbankingnews.com

Rafferty Asset Management LLC Reduces Stock Position in Neurocrine Biosciences, Inc. $NBIX

August 30 at 5:28 AM | marketbeat.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 30 at 2:40 AM | marketbeat.com

Ieq Capital LLC Sells 20,887 Shares of Neurocrine Biosciences, Inc. $NBIX

August 29, 2025 | marketbeat.com

Caisse DE Depot ET Placement DU Quebec Sells 348,711 Shares of Neurocrine Biosciences, Inc. $NBIX

August 29, 2025 | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Corebridge Financial Inc.

August 29, 2025 | marketbeat.com

APG Asset Management N.V. Sells 2,247 Shares of Neurocrine Biosciences, Inc. $NBIX

August 29, 2025 | marketbeat.com

Affinity Asset Advisors LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX

August 28, 2025 | marketbeat.com

Walleye Capital LLC Acquires 69,737 Shares of Neurocrine Biosciences, Inc. $NBIX

August 28, 2025 | marketbeat.com

Allstate Corp Increases Stake in Neurocrine Biosciences, Inc. $NBIX

August 28, 2025 | marketbeat.com

Martingale Asset Management L P Has $353,000 Stock Position in Neurocrine Biosciences, Inc. $NBIX

August 28, 2025 | marketbeat.com

Price T Rowe Associates Inc. MD Boosts Position in Neurocrine Biosciences, Inc. $NBIX

August 27, 2025 | marketbeat.com

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

August 26, 2025 | prnewswire.com

BI Asset Management Fondsmaeglerselskab A S Sells 7,385 Shares of Neurocrine Biosciences, Inc. $NBIX

August 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, BIIB, INCY, and NBIX Company Descriptions

Biogen NASDAQ:BIIB

$139.63 +7.41 (+5.60%)

Closing price 04:00 PM Eastern

Extended Trading

$139.47 -0.16 (-0.11%)

As of 07:59 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$85.98 +1.37 (+1.62%)

Closing price 04:00 PM Eastern

Extended Trading

$86.06 +0.08 (+0.10%)

As of 07:31 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Ionis Pharmaceuticals NASDAQ:IONS

$57.49 +14.86 (+34.86%)

Closing price 04:00 PM Eastern

Extended Trading

$57.85 +0.36 (+0.63%)

As of 07:58 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Neurocrine Biosciences NASDAQ:NBIX

$141.92 +2.32 (+1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$141.90 -0.02 (-0.01%)

As of 04:55 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time